NASDAQ:CVAC CureVac (CVAC) Stock Forecast, Price & News $9.36 +0.25 (+2.74%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$9.14▼$9.4250-Day Range$6.43▼$10.4652-Week Range$5.63▼$18.58Volume305,197 shsAverage Volume651,199 shsMarket Capitalization$2.10 billionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability CureVac MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.4% Upside$21.00 Price TargetShort InterestBearish4.63% of Float Sold ShortDividend StrengthN/ASustainability-1.63Upright™ Environmental ScoreNews Sentiment0.17Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.04) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector559th out of 983 stocksPharmaceutical Preparations Industry276th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingCureVac has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, CureVac has a forecasted upside of 124.4% from its current price of $9.36.Amount of Analyst CoverageCureVac has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.63% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in CureVac has recently increased by 19.39%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCureVac has received a 79.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "mRNA vaccines" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CureVac is -1.63. Previous Next 2.3 News and Social Media Coverage News SentimentCureVac has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CureVac this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CVAC on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows2 people have added CureVac to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from ($1.04) to ($1.10) per share.Price to Book Value per Share RatioCureVac has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CureVac (NASDAQ:CVAC) StockCureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.Read More Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address CVAC Stock News HeadlinesJune 2, 2023 | americanbankingnews.comCureVac (NASDAQ:CVAC) Shares Up 3.7%June 1, 2023 | finance.yahoo.comCureVac First Quarter 2023 Earnings: EPS Beats Expectations, Revenues LagJune 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. June 1, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: MustGrow Biologics (OtherMGROF), CureVac (CVAC) and Xenon (XENE)May 30, 2023 | finance.yahoo.comCureVac Announces Financial Results for the First Quarter of 2023 and Provides Business UpdateMay 24, 2023 | finance.yahoo.comCureVac N.V.'s (NASDAQ:CVAC) market cap surged US$362m last week, private equity firms who have a lot riding on the company were rewardedMay 24, 2023 | 247wallst.comPeter Kolchinsky-led RA Capital's New Positions Feature CureVac, Mineralys, Pilant, Enliven TherapeuMay 22, 2023 | americanbankingnews.comCureVac (CVAC) to Release Earnings on TuesdayJune 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 22, 2023 | americanbankingnews.comCureVac (CVAC) to Release Quarterly Earnings on TuesdayMay 19, 2023 | finance.yahoo.comCureVac Announces Developments in Patent Litigation with Pfizer/BioNTechMay 8, 2023 | finance.yahoo.comCureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSKMay 2, 2023 | finance.yahoo.comCureVac N.V. (NASDAQ:CVAC) Q4 2022 Earnings Call TranscriptMay 1, 2023 | finance.yahoo.comAnalyst Forecasts Just Became More Bearish On CureVac N.V. (NASDAQ:CVAC)April 30, 2023 | americanbankingnews.comFY2023 EPS Estimates for CureVac Reduced by Jefferies Financial Group (NASDAQ:CVAC)April 28, 2023 | americanbankingnews.comCureVac (NASDAQ:CVAC) Price Target Cut to $24.00April 27, 2023 | americanbankingnews.comJefferies Financial Group Weighs in on CureVac's Q1 2023 Earnings (NASDAQ:CVAC)April 25, 2023 | seekingalpha.comCureVac: Potential Of mRNA Tech Beyond Covid-19 Vaccine DevelopmentApril 25, 2023 | seekingalpha.comCureVac N.V. 2022 Q4 - Results - Earnings Call PresentationApril 18, 2023 | finance.yahoo.comCureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023April 17, 2023 | finance.yahoo.comCureVac N.V.'s (NASDAQ:CVAC) Shares May Have Run Too Fast Too SoonApril 8, 2023 | americanbankingnews.comCureVac (NASDAQ:CVAC) Trading 4.8% Higher March 30, 2023 | americanbankingnews.comCureVac (NASDAQ:CVAC) Shares Down 2.2% March 23, 2023 | finance.yahoo.comAs CureVac N.V.'s market cap (NASDAQ:CVAC) drops to US$1.4b, insiders might be questioning their decision to buy earlier this yearMarch 17, 2023 | barrons.comCureVac N.V.March 17, 2023 | finance.yahoo.comCureVac N.V. (CVAC)February 12, 2023 | markets.businessinsider.comEQS-News: CureVac Announces Closing of $250 million Follow-on Public Offering of Common SharesSee More Headlines CVAC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVAC Company Calendar Last Earnings11/29/2020Today6/03/2023Next Earnings (Estimated)7/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CVAC CUSIPN/A CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees1,049Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+124.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio7.61 Quick Ratio3.58 Sales & Book Value Annual Sales$72.33 million Price / Sales28.97 Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book2.74Miscellaneous Outstanding Shares223,840,000Free Float219,029,000Market Cap$2.10 billion OptionableNot Optionable Beta2.87 Key ExecutivesDr. Franz-Werner Haas L.L.M. (Age 53)LL.M., LLD, Ph.D., CEO, Member of Management Board & MD Comp: $575.16kMr. Pierre Kemula B.Sc. (Age 48)MD, CFO & Member of Management Board Comp: $606.97kDr. Ulrike Gnad-Vogt M.D. (Age 51)Ph.D., Interim Chief Devel. Officer, Sr. VP & Area Head of Oncology and Member of Exec. Board Comp: $232.53kDr. Igor Splawski M.Sc. (Age 54)Ph.D., Chief Scientific Officer & Member of Management Board Comp: $430.33kDr. Antony Blanc Ph.D. (Age 53)MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board Comp: $370.81kMr. Malte Greune Ph.D. (Age 58)COO, Member of Management Board & MD Comp: $354.23kDr. Sarah FakihVP Corp. Communications & Investor RelationsMr. Marco Rau L.L.M.Ph.D., Gen. CounselMr. Thorsten SchullerHead of Corp. CommunicationsSlavica Stevanovic-HeckHead of HRMore ExecutivesKey CompetitorsVentyx BiosciencesNASDAQ:VTYXAbCellera BiologicsNASDAQ:ABCLViking TherapeuticsNASDAQ:VKTXHUTCHMEDNASDAQ:HCMHarmony BiosciencesNASDAQ:HRMYView All CompetitorsInstitutional OwnershipBalyasny Asset Management L.P.Sold 284,532 shares on 5/16/2023Ownership: 0.498%State Street CorpBought 8,821 shares on 5/16/2023Ownership: 0.119%Geode Capital Management LLCBought 1,188 shares on 5/16/2023Ownership: 0.075%Ghisallo Capital Management LLCBought 100,000 shares on 5/16/2023Ownership: 0.045%Susquehanna International Group LLPBought 48,300 shares on 5/16/2023Ownership: 0.000%View All Institutional Transactions CVAC Stock - Frequently Asked Questions Should I buy or sell CureVac stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVAC shares. View CVAC analyst ratings or view top-rated stocks. What is CureVac's stock price forecast for 2023? 3 analysts have issued 12-month target prices for CureVac's shares. Their CVAC share price forecasts range from $18.00 to $24.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 124.4% from the stock's current price. View analysts price targets for CVAC or view top-rated stocks among Wall Street analysts. How have CVAC shares performed in 2023? CureVac's stock was trading at $6.03 at the beginning of the year. Since then, CVAC stock has increased by 55.2% and is now trading at $9.36. View the best growth stocks for 2023 here. Are investors shorting CureVac? CureVac saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,310,000 shares, an increase of 19.4% from the April 30th total of 3,610,000 shares. Based on an average daily trading volume, of 561,300 shares, the short-interest ratio is currently 7.7 days. Approximately 4.6% of the shares of the company are short sold. View CureVac's Short Interest. When is CureVac's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023. View our CVAC earnings forecast. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) issued its quarterly earnings data on Sunday, November, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($54.37) by $54.13. What ETFs hold CureVac's stock? ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree BioRevolution Fund (WDNA), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO). When did CureVac IPO? (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers. What is CureVac's stock symbol? CureVac trades on the NASDAQ under the ticker symbol "CVAC." Who are CureVac's major shareholders? CureVac's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (1.70%), BlackRock Inc. (0.88%), Balyasny Asset Management L.P. (0.50%), Alyeska Investment Group L.P. (0.47%), State Street Corp (0.12%) and Credit Suisse AG (0.11%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CureVac's stock price today? One share of CVAC stock can currently be purchased for approximately $9.36. How much money does CureVac make? CureVac (NASDAQ:CVAC) has a market capitalization of $2.10 billion and generates $72.33 million in revenue each year. How many employees does CureVac have? The company employs 1,049 workers across the globe. How can I contact CureVac? CureVac's mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The official website for the company is www.curevac.com. The company can be reached via phone at 49-70-71988-30, via email at investors@curevac.com, or via fax at 49-7071-9883. This page (NASDAQ:CVAC) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.